The development of payload resistant cell lines to study antibody-drug conjugate resistance in high-grade serous ovarian cancer
Year: 2026
Type: preprint
Abstract: Antibody-drug conjugates (ADCs) are increasingly used to treat recurrent high grade serous ovarian cancer (HGSOC), yet their effects on tumor biology and subsequent treatment response remain poorly understood. We evaluated the short-term effects of ADCs and their respective payloads on ADC receptor expression and developed payload resistant HGSOC cell lines to determine how acquired payload resistance influences response to subsequent ADC therapy. Matched platinum sensitive and resistant HGSOC cell lines were exposed to trastuzumab deruxtecan (T-DXd) and mirvetuximab soravtansine (MIRV), or their respective payloads, DXd and DM4. DXd and DM4 resistant cell lines were generated through sequential payload dose escalation and characterized for ADC receptor expression and response to T-DXd, MIRV, and sacituzumab govitecan (SG). Short-term T-DXd and MIRV exposure reduced their respective targets in chemosensitive cells and altered several clinically relevant ADC receptors. DXd and DM4 resistant cell lines were developed and confirmed resistant. Notably, DM4 resistant cells showed increased T-DXd sensitivity, whereas DXd resistant cells exhibited reduced sensitivity to MIRV and SG. These findings demonstrate that ADC exposure dynamically alters receptor expression and that acquired payload resistance can differentially influence subsequent ADC response. Further investigation may identify biomarkers of ADC resistance and inform upon ADC sequencing strategies in HGSOC.
Source: Research Square
Institution: Brown University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Swim Across America
OpenAlex ID: W7235231457
